User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Primary tabs

download
  • Open access
  • PDF
  • 511.96 K
Fox, Robert J Miller, David H Phillips, J Theodore Hutchinson, Michael Havrdova, Eva Sindic, Christian [UCL]

In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. (Funded by Biogen Idec; CONFIRM ClinicalTrials.gov number, NCT00451451.).

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2012
Language Anglais
Journal information "The New England journal of medicine" - Vol. 367, no. 12, p. 1087-97 (2012)
Peer reviewed yes
issn 1533-4406
Publication status Publié
Affiliation UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire
MESH Subject Administration, Oral ; Intention to Treat Analysis ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting ; Peptides ; Adult ; Brain ; Double-Blind Method ; Female ; Fumarates ; Humans ; Immunosuppressive Agents ; Infection
Links
Bibliographic reference Fox, Robert J ; Miller, David H ; Phillips, J Theodore ; Hutchinson, Michael ; Havrdova, Eva ; et. al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.. In: The New England journal of medicine, Vol. 367, no. 12, p. 1087-97 (2012)
Permanent URL http://hdl.handle.net/2078.1/124404